549502-23-0

Upstream product

• 146431-18-7 (Z)-1,3-bis(trimethylsiloxy)-1-tert-butoxybuta-1,3-diene 
• 60656-87-3 benzyloxyacetoaldehyde 
• 106058-91-7 (+)-(R)-ethyl 4-benzyloxy-3-hydroxybutanoate 
• 540-88-5 acetic acid tert-butyl ester 
• 147849-63-6 tert-butyl (5R)-3-oxo-5-hydroxy-6-benzyloxyhexanoate 

Downstream Products

• 609828-56-0 7-(9-{(1E)(3S,4S)-4-[(4-methoxyphenyl)methoxy]-3,5-dimethylhex-1-enyl}(7S,9R)-6,10-dioxospiro[4.5]dec-7-yl)-1-{9-[(1S)-1-methyl-2-(phenylmethoxy)ethyl](7S,9R)-6,10-dioxaspiro[4.5]dec-7-yl}(4S,6S)-4-hydroxy-6-(tert-butyldimethylsilyloxy)heptan-2-one 
• 609828-47-9 tert-butyl (6E)(3S,8S,9S,5R)-3,5-bis(tert-butyldimethylsilyloxy)-9-[(4-methoxyphenyl)methoxy]-8,10-dimethyl-undec-6-enoate 
• 1026361-09-0 tert-butyl 2-(9-{(1E)(3S,4S)-4-[(4-methoxyphenyl)methoxy]-3,5-dimethylhex-1-enyl}(7S,9R)-6,10-dioxaspiro[4.5]dec-7-yl)acetate 
• 609828-51-5 2-(9-{(1E)(3S,4S)-4-[(4-methoxyphenyl)methoxy]-3,5-dimethylhex-1-enyl}(7S,9R)-6,10-dioxaspiro[4.5]dec-7-yl)ethanal 
• 609828-44-6 tert-butyl (3S,5S)-3,5-bis(tert-butyldimethylsilyloxy)-6-(phenylmethoxy)hexanoate 

Relevant academic research and scientific papers

Enantioselective synthesis of oasomycin A, part II: Synthesis of the C29-C46 subunit

(Chemical Equation Presented) Putting the pieces together: The total synthesis of the natural macrolide oasomycin A has been realized. Key fragment couplings include an anti-Felkin selective aldol addition (green), Kociensky-Julia olefinations (red), and

Synthesis of the antifungal macrolide antibiotic (+)-roxaticin

The total synthesis of the antifungal macrolide antibiotic roxaticin has been accomplished. The synthesis relies principally on aldol and directed reduction steps to construct the extended 1,3-polyol array present in the natural product. Three principal n

Diastereoselective synthesis of syn-3,5-dihydroxyesters via ruthenium-catalyzed asymmetric transfer hydrogenation

The asymmetric transfer hydrogenation of chiral 5-hydroxy-3-ketoesters in 2-propanol using chlororuthenium(II)arene/β-amino alcohol in situ catalyst combinations or a pre-synthesized Ru-{β-amino alcohol} true catalyst, provides syn-3,5-dihydroxyesters in

Asymmetric synthesis of bryostatin 2

The potent bryostatin antitumor agents are currently in phase II clinical trials for the treatment of a variety of forms of cancer. Aldol reactions and directed reductions are among the essential steps for the formation of fragments A-C in the total synthesis of the title compound. Coupling of these fragments by sulfone-based olefination and alkylation reactions was followed by macrocyclization and introduction of the enoate moieties on rings B and C.